Expression of microRNAs in patients with gestational diabetes mellitus: a systematic review and meta-analysis,Acta Diabetologica

当前位置： X-MOL 学术 › Acta Diabetol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Expression of microRNAs in patients with gestational diabetes mellitus: a systematic review and meta-analysis
Acta Diabetologica ( IF 3.1 ) Pub Date : 2022-12-17 , DOI: 10.1007/s00592-022-02005-8
Jianhua Li ₁ , Bei Gan ₁ , Lin Lu ₁ , Lihong Chen ₁ , Jianying Yan ₂

Affiliation

Background

MicroRNAs (miRNA) are noncoding RNAs that play a central role in governing various physiological and pathological processes. There are few studies on miRNA involvement in gestational diabetes mellitus (GDM). In this study, we performed a meta-analysis of the miRNA expression profiling from GDM patients.

Methods

Guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, we performed a systematic search of the PubMed, Cochrane Library, and EMBASE databases from inception to December 20, 2021, to retrieve the original research studies. All the relevant data were retrieved, analyzed, and summarized.

Results

Six studies (252 GDM cases and 309 controls) were included and analyzed. The six studies reported the expressions of 21 miRNAs in GDM cases. Of the 21 miRNAs, 12 miRNAs were found to be upregulated, and two were downregulated. The top three most consistently reported upregulated miRNAs were miR-16-5p (mean differences of fold change are 1.25, 95% CI = 0.04–2.46, P = 0.040), miR-19a-3p (mean differences of fold change are 2.90, 95% CI = 1.45–4.35, P = 0.001), and miR-19b-3p (mean differences of fold change are 3.10, 95% CI = 0.94–5.25, P = 0.005). miR-155-5p and miR-21-3p were found to be downregulated.

Conclusions

The results indicate that several miRNAs may be used as markers for diabetes gestational diabetes mellitus. In the future, more studies are needed to validate the findings of our study.

中文翻译：

microRNAs 在妊娠糖尿病患者中的表达：一项系统评价和荟萃分析

背景

微小 RNA (miRNA) 是非编码 RNA，在控制各种生理和病理过程中起着核心作用。关于 miRNA 参与妊娠期糖尿病 (GDM) 的研究很少。在这项研究中，我们对 GDM 患者的 miRNA 表达谱进行了荟萃分析。

方法

在系统评价和荟萃分析协议的首选报告项目的指导下，我们对 PubMed、Cochrane 图书馆和 EMBASE 数据库从开始到 2021 年 12 月 20 日进行了系统搜索，以检索原始研究。检索、分析和总结了所有相关数据。

结果

纳入并分析了六项研究（252 例 GDM 病例和 309 例对照）。这六项研究报告了 21 种 miRNA 在 GDM 病例中的表达。在 21 种 miRNA 中，发现 12 种 miRNA 上调，2 种下调。前三个最一致报告的上调 miRNA 是 miR-16-5p（倍数变化的平均差异为 1.25，95% CI = 0.04–2.46，P = 0.040），miR-19a-3p（倍数变化的平均差异为 2.90， 95% CI = 1.45–4.35，P = 0.001）和 miR-19b-3p（倍数变化的平均差异为 3.10，95% CI = 0.94–5.25，P = 0.005）。发现 miR-155-5p 和 miR-21-3p 被下调。